Skip to main content

Table 4 Multivariate analysis for overall survival

From: Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

  HR (95% CI) P value
Treatment with GEM 0.34 (0.20–0.57) 0.0001a
Age <70 1.09 (0.68–1.77) 0.7104
Male 0.89 (0.53–1.48) 0.6490
T factor T2 0.49 (0.25–0.94) 0.0314a
N factor N0 0.75 (0.26–2.19) 0.6046
UICC stage VIIA 1.23 (0.36–4.26) 0.7415
Resection status R0 0.38 (0.20–0.73) 0.0033a
  1. aStatistically significant difference.
  2. CI confidence interval; GEM gemcitabine; HR hazard ratio.